Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study

Malizia, Tecla; Tejada, M.; Marchetti, Francesca; Favini, P.; Pizzarelli, Giampaolo; Campa, Mario; Senesi, Sonia

doi:10.1093/jac/41.suppl_2.29

Cited by 18 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown a synergistic effect of macrolides and PPIs, as indicated by the increased success rate of eradication therapy for Helicobacter pylori in patients receiving macrolides and PPIs versus macrolides alone, and this effect does not appear to be pH-dependent in vitro. The macrolide clarithromycin also inhibits the metabolism of the PPI omeprazole 33,34 . Moreover, we also observed an increase in microbial functions characteristic of the oral bacteria, such as carbohydrate degradation pathways, and an increase in pathways involved in L-arginine biosynthesis.…”

Section: Discussionmentioning

confidence: 99%

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

et al. 2020

View full text Add to dashboard Cite

The human gut microbiota has now been associated with drug responses and efficacy, while chemical compounds present in these drugs can also impact the gut bacteria. However, drug-microbe interactions are still understudied in the clinical context, where polypharmacy and comorbidities co-occur. Here, we report relations between commonly used drugs and the gut microbiome. We performed metagenomics sequencing of faecal samples from a population cohort and two gastrointestinal disease cohorts. Differences between users and nonusers were analysed per cohort, followed by a meta-analysis. While 19 of 41 drugs are found to be associated with microbial features, when controlling for the use of multiple medications, proton-pump inhibitors, metformin, antibiotics and laxatives show the strongest associations with the microbiome. We here provide evidence for extensive changes in taxonomy, metabolic potential and resistome in relation to commonly used drugs. This paves the way for future studies and has implications for current microbiome studies by demonstrating the need to correct for multiple drug use.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

et al. 2020

View full text Add to dashboard Cite

show abstract

“…сравнивалась активность эритромицина и ази тромицина в отношении H. pylori. МПК 50 в данном иссле довании составляла 0,5 мг/л для обоих препаратов [33].…”

Section: Discussionunclassified

Comparison of in vitro activity of various macrolides against Helicobacter pylori

Дехнич

Иванчик

Kozlov

2018

CMAC

View full text Add to dashboard Cite

Objective. Compare the in vitro activity of clarithromycin, erythromycin, azithromycin and josamycin against the collection of H. pylori strains isolated in 2010–2017 in Smolensk. Materials and Methods. H. pylori strains were collected prospectively from biopsy specimens of the gastric mucosa. Antimicrobial susceptibility testing of H. pylori was performed by the agar dilution method. Interpretation of the results of the susceptibility determination for clarithromycin was carried out in accordance with the recommendations of EUCAST (v 8.0) 2018. The resistance breakpoints for erythromycin, azithromycin, and josamycin were all set at ≥1.0 mg/L. For comparison of the results, the value of the minimal inhibitory concentrations of the tested antibiotic inhibiting the growth of 50% (MIC50) and 90% (MIC90) of H. pylori strains was used. Results. A total of 276 H. pylori strains were tested. 90% of the MIC values of clarithromycin were in the range from 0.015 to 0.125 mg/l. The percentages of resistance were as follows: clarithromycin 5.1%, azithromycin 7.5%, erythromycin 8%, josamycin 23.2%. Clarithromycin demonstrated significantly higher activity in suppressing the growth of H. pylori strains than azithromycin, erythromycin, and josamycin. Conclusions. Among the tested macrolide antibiotics maximal anti-H. pylori activity in vitro was observed in clarithromycin.

show abstract

“…The choice of tinidazol was governed by a slightly longer of 12–13 h when compared with 8 h for metronidazol and previous reports of a good effect in other studies 22, 23 . The pharmacological data of a long for both antibiotics and studies in vitro indicating that lansoprazole may act synergetic on azitromycin 24 motivated our choice of a one‐dose per day 6 days PPI‐based triple therapy that in theory would be comparable with a twice daily 7 days therapy.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication in children and adolescents by a once daily 6‐day treatment with or without a proton pump inhibitor in a double‐blind randomized trial

Tindberg

Casswall

Blennow

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYAim: To evaluate two simplified Helicobacter pylori eradication treatment alternatives for children and adolescents. Methods: Study subjects were identified by enzymelinked immunosorbent assay and immunoblot in a family screening project. Helicobacter pylori infected 10-21 year olds were offered treatment, individuals with abdominal pain underwent upper endoscopy and those with peptic ulcers were excluded. Participants were randomized to either azithromycin 500 mg daily and tinidazole 500 mg two tablets daily in combination with lansoprasole 30 mg daily for 6 days (ATL-group) or with placebo (ATP-group). Urea Breath Test was performed at inclusion and after a minimum of 6 weeks after end of therapy.Results: In total, 131 individuals were randomized, of whom 31 (24%) had undergone upper endoscopy. Full compliance was achieved in 93% (122 of 131). The intention-to-treat eradication rate was 67% (44 of 66) and 58% (38 of 65) for the ATL-and the ATP-group, respectively. Conclusion: The double-blind randomized clinical trial did not identify a simplified, successful once daily H. pylori treatment for children and adolescents. Thus, twice daily proton pump inhibitor (PPI)-based triple therapies for 7 days remain as the choice of treatment in children. Further, powerful and controlled studies are needed to elucidate the best treatment strategies for H. pylori eradication in this age group.

show abstract

Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study

Cited by 18 publications

References 20 publications

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

Comparison of in vitro activity of various macrolides against Helicobacter pylori

Helicobacter pylori eradication in children and adolescents by a once daily 6‐day treatment with or without a proton pump inhibitor in a double‐blind randomized trial

Contact Info

Product

Resources

About